CROSSJECT's 2025 Financial Results Indicate Positive Trajectory

On March 25, 2026, CROSSJECT published its financial results for 2025, highlighting significant progress. Operating revenue increased by 12.25% to €14.9 million, and the operating result improved from -€13.0 million in 2024 to -€11.6 million. The net loss decreased to €-10.4 million from €-12.8 million. Additionally, CROSSJECT's available cash stood at €5.1 million, supplemented by a €2.8 million research tax credit, totaling €7.9 million.

Further development of the ZENEO® platform, specifically for ZEPIZURE® Junior, and increased BARDA funding to $43.3 million, underscored CROSSJECT's strategic advancement. The company also announced a reinforced governance structure and financial foothold through capital increases and convertible bonds. These efforts set the stage for future commercialization in the U.S. and potential peak annual sales of €1 billion.